Interview with Jonathan Zhu, General Manager, Celgene China
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Address: No. 222, Huangpu District, Shanghai Yan’an East Road
, Bund Center, 1102 – Room 1104
Zip: 200002 ,China
Tel: +86 216 133 9333
The new base is committed to providing innovative medicines that can really change the life for patients. Our mission is to build a global enterprise based biopharmaceutical, while focusing on the exploration, development, and commercialization of pharmaceutical products for the treatment of cancer and other serious diseases such as immune and inflammatory.
Major medical centers about 300 a number of new base compounds of clinical trials. Compounds of these studies are for blood and solid tumor cancer patients suffering from an incurable research, including multiple myeloma, bone marrow hyperplasia anomaly syndrome, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL ), myelofibrosis, small cell lung cancer and prostate cancer.
As committed to the clinical achievements, we are equally committed to providing patient support, which is the guiding principle of the new base. We believe that all patients should be given the opportunity to benefit from our research. New base by the industry-leading program patients were placed in the first, to provide information, support, and our innovative therapies.
Revlimid
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement,…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established…
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…
The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic,…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.…
See our Cookie Privacy Policy Here
